More doors, more questions
October 2026 combination, observational and kidney reports
Did every new use work out?
Subject One finally reaches the desk labeled TODAY. Some doors have opened; the Alzheimer’s folder carries a disappointing result. “Do we keep that page?” he asks. “Especially that page,” says Doctide. The clerk adds a follow-up appointment. The story is longer, but it is not a victory in every room.
What changes here
No. The Alzheimer’s trials did not establish slower disease progression. An honest history keeps the unsuccessful studies, too. [5]
Read the study details & dates
A liver-disease milestone with conditions
Wegovy gained accelerated approval for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. Approval rested on improvements in liver inflammation and scarring; continued study must establish longer-term clinical benefit. [1]
A door that did not open: Alzheimer’s disease
The evoke and evoke+ Phase 3 trials did not establish that oral semaglutide slowed progression of early symptomatic Alzheimer’s disease compared with placebo. A plausible biological idea did not become a demonstrated clinical benefit in these trials. [5]
An oral Wegovy option
Oral Wegovy received US approval. Product, route and population distinctions still matter; approval of one preparation does not make every semaglutide preparation equivalent. [2]
Wegovy HD
FDA approved a higher-dose Wegovy product. Its announcement also highlighted more frequent altered skin sensations and further investigation of that finding. Greater average weight reduction does not remove safety questions. [3]
A European recommendation for a combination product—not a final decision
CHMP recommended a change to Kyinsu’s existing indication for adults with insufficiently controlled type 2 diabetes. Kyinsu combines insulin icodec with semaglutide in a once-weekly injection; it is not semaglutide alone or a new obesity approval. The opinion concerns treatment alongside diet, exercise and oral diabetes medicines. EMA states that the updated product information will follow a European Commission decision. This is a regulatory recommendation, not a new trial result or a completed approval of the change. The existing EMA overview identifies low blood glucose and gastrointestinal reactions among the combination’s most common adverse effects. [6] [7]
A post hoc women’s analysis of an investigational combination
Novo Nordisk presented sponsor-led post hoc analyses from REDEFINE 1 (NCT05567796), a 68-week phase 3a randomized trial in adults without diabetes who had obesity or overweight with at least one related complication. Among 2,309 women across the trial, the company release highlighted a 25.0% mean weight reduction with once-weekly CagriSema 2.4 mg/2.4 mg (cagrilintide plus semaglutide) versus 3.0% with placebo under the efficacy estimand, which assumes treatment adherence. A separate analysis of 1,902 women assigned to CagriSema or placebo reported mean reductions of 26.7%, 24.8% and 23.1% for premenopausal, perimenopausal and postmenopausal participants, respectively. These exploratory analyses concern the fixed-dose combination—not semaglutide alone—and do not prove that menopause stage changes treatment effect. They are not a regulatory approval, and these particular analyses were reviewed as congress material and a sponsor release rather than a peer-reviewed full paper. [8] [9] [10]
Hormone therapy: an association that needs prospective testing
In a retrospective, 1:2 propensity-matched cohort of 2,379 women aged at least 45 with BMI at least 27, semaglutide users taking menopause hormone therapy lost 9.8% versus 8.2% at nine months (p<0.001). Matching covered age, BMI, prior obesity medication and diabetes. Oral/transdermal estrogen with or without progesterone counted as hormone therapy; semaglutide formulation was unspecified. Requiring at least 12 months of treatment selects persistent users. Residual confounding remains; this conference abstract does not establish causation or recommend hormone therapy for weight loss. It reports no safety analysis. [11]
Oral semaglutide: a small, short kidney study
A single-center randomized study assigned 92 patients with diabetic kidney disease and persistent macroalbuminuria to oral semaglutide or placebo for 16 weeks, alongside background kidney therapies. Urinary albumin-to-creatinine ratio fell 32% and 54% in the 3 mg and 7 mg study arms, respectively, versus 12% with placebo. The abstract reports placebo-adjusted reductions of 21% (p=0.031) and 42% (p<0.0001); its adjustment method is not described. These are albuminuria findings, not evidence of fewer kidney-failure events or equivalent effects across oral and injected products. Most adverse events were mild-to-moderate gastrointestinal events; serious-event counts were not supplied. Phase, registry identifier, arm sizes, confidence intervals, blinding and missing-data methods are not reported in the abstract. A full report is needed before firm conclusions. [12]
Serious kidney injury: a case report with incomplete recovery
ASN SA-PO0338 describes a 72-year-old woman with type 2 diabetes and stage 3 chronic kidney disease who developed vomiting and dizziness two months after starting semaglutide. Creatinine rose from about 1.5 to 9.8 mg/dL; biopsy showed acute tubular injury. Semaglutide, metformin and losartan were stopped. Without dialysis or immunosuppression, creatinine improved to 2.4 mg/dL at two months, still above baseline. Semaglutide was not restarted; losartan was. The authors report an association and propose gastrointestinal fluid loss, pre-existing kidney disease and concurrent renin–angiotensin-system inhibition as contributing factors. This single uncontrolled human case cannot establish causality or incidence. Brand, route and formulation are unspecified; there is no comparator, trial phase or registry identifier. [13]
Dialysis-requiring injury: suspected contribution, not proven causation
ASN SA-PO0336 describes a 50-year-old man with a heart transplant, chronic kidney disease and diabetes who developed gastrointestinal symptoms a week after starting semaglutide. He continued exercise and several medicines despite reduced intake. Creatinine reached 9.31 mg/dL; biopsy showed severe tubular injury with myoglobin casts and patchy tubulointerstitial nephritis. Four hemodialysis treatments were required, followed by reported recovery to baseline filtration. Semaglutide was not resumed. The authors suspected that semaglutide initiation contributed to acute kidney injury; dehydration, other medicines and comorbidities complicate attribution. This uncontrolled human case does not prove drug causation or estimate frequency. Brand, route and formulation are unspecified; no comparator, trial phase or registry identifier is reported. [14]
Carolina Infusion compounded syringes: separate sterility-assurance recall
FDA enforcement event 99867 records a voluntary Class II recall by Carolina Infusion, LLC, Ridgeland, South Carolina, distributed nationwide within the United States. The affected records (D-0018-2027, D-0019-2027 and D-0026-2027) cover specified lots of compounded injectable semaglutide alone and semaglutide/cyanocobalamin (vitamin B12), supplied in patient-specific syringes. FDA lists lack of sterility assurance related to formulation water and processing equipment. The linked records identify the precise formulations, concentrations, lots and beyond-use dates; these identifiers are not administration instructions. This is a product-quality enforcement action, not a clinical trial or a recall of Ozempic or Wegovy. The October 14 dataset lists the recall as ongoing; that historical status does not independently establish its status today. The records contain no patient injury or death counts or patient-level causality assessments, so no absence of harm can be inferred. These are earlier events newly documented in this journey, not a recall initiated today. [15]
Vomiting prevention: a short challenge study, not routine treatment
Vanda reported phase 3 Study 3601 results for oral tradipitant versus placebo during semaglutide exposure. Any vomiting occurred in 61/142 (43.0%) versus 96/164 (58.5%); site-adjusted p=0.006, an absolute difference of 15.5 percentage points. Participants received a single semaglutide exposure without routine gradual titration; this cannot establish long-term effectiveness in everyday care or benefits with tirzepatide or retatrutide. Higher-burden vomiting analyses were post hoc. The sponsor reported no new safety signals but supplied no numerical serious-event or death counts, confidence intervals, or complete missing-data/estimand description. An intended supplemental application is not approval for this use. These are sponsor-reported results, not a reviewed peer-reviewed full report. Registry NCT07446439 describes adults aged 18–65 with BMI 25 to below 40, excluding diabetes, randomized to oral tradipitant or placebo, with a one-week primary diary endpoint. Its April record still lists recruiting and estimated enrollment 280; that stale entry cannot establish recruitment today or replace the announcement’s analysis denominators. [16] [17]
Reporting signals cannot rank clinical safety
A retrospective FAERS analysis (January 2022–June 2026) compared semaglutide-only and tirzepatide-only reports using reporting odds ratios, adjusted regression and false-discovery-rate correction. Semaglutide reports more often involved gastric-emptying impairment, obstruction/ileus, kidney injury, pancreatitis, vomiting and optic ischaemic neuropathy; alopecia reporting favored the opposite direction. Adjusted hospitalization and death reporting odds were higher with semaglutide. These are reporting patterns, not incidence, comparative clinical risk or established causality. The abstract does not resolve formulation-specific risks. Only the publisher abstract was reviewed; full tables were inaccessible. [18] [19]
Brazil approves oral Wegovy for adult weight management
This is a Brazil-specific regulatory decision for oral Wegovy, not a new approval of every semaglutide preparation. Anvisa announced approval for adults with obesity (BMI at least 30), or overweight (BMI at least 27 and below 30) with at least one weight-related comorbidity, alongside reduced-calorie diet and physical activity. The agency identifies OASIS 4 as the principal supporting trial. This entry records the approval only; it does not add a new trial analysis or imply that oral and injected products are interchangeable. The announcement provides no detailed serious-adverse-event table, and approval does not remove the medicine’s safety limitations. Anvisa’s notice was reviewed; its linked official-gazette resolution could not be retrieved. [20]
FDA requires a warning about potentially permanent vision loss
FDA requires a NAION warning for marketed GLP-1 medicines, explicitly including Ozempic, Rybelsus and Wegovy. NAION is a rare optic-nerve condition that can cause permanent vision loss. FDA concludes there is a potential increased risk, not proven causation in every reported case. Its pooled analysis of 126 randomized trials found 6.4 versus 3.8 probable events per 100,000 person-years with GLP-1 medicines versus placebo or other glucose-lowering medicines. These are class-level rates, not estimates specific to this medicine or formulation. In a separate Sentinel cohort of adults with type 2 diabetes, risk was higher versus DPP-4 inhibitors but not statistically significantly higher versus SGLT-2 inhibitors. This records the required labeling change; it does not confirm every individual label has already been revised. FDA advises prompt medical contact for sudden painless vision loss or other visual changes. [21]
What this does not establish
The history continues after approval. This is a selection of major documented milestones, not the full confidential development dossier or a complete prescribing guide.
Original sources
- FDA MASH accelerated approval
- Novo Nordisk SEC-filed oral Wegovy announcement
- FDA Wegovy HD approval (March 2026)
- Current Wegovy prescribing information
- evoke and evoke+ primary trial publication (2026)
- EMA CHMP Kyinsu variation opinion, adopted October 15 and published October 16, 2026; Commission decision pending
- EMA Kyinsu overview and existing authorisation: insulin icodec plus semaglutide
- Novo Nordisk sponsor release on the REDEFINE 1 post hoc analyses (October 20, 2026)
- The Menopause Society 2026 congress poster: CagriSema by menopause status and hormone-therapy use
- ClinicalTrials.gov record NCT05567796 (REDEFINE 1)
- Castaneda et al., The Menopause Society 2026, abstract S-1, page 1 (retrospective conference study)
- Igamberdieva and Daminov, ASN Kidney Week 2026, FR-PO0499 (primary conference abstract)
- Nair et al., ASN Kidney Week 2026, SA-PO0338 (human case-report abstract; October 24 presentation)
- Marnet et al., ASN Kidney Week 2026, SA-PO0336 (human case-report abstract; October 24 presentation)
- FDA enforcement event 99867, records D-0018-2027, D-0019-2027 and D-0026-2027; report October 14, 2026; retrieved October 26 (dataset last updated October 14)
- Vanda sponsor release: Study 3601 results, October 27, 2026
- ClinicalTrials.gov NCT07446439, April 20 record accessed October 27, 2026
- Arslan, Endocrine: publisher abstract, DOI 10.1007/s12020-026-04840-z (issue date displayed December 1, 2026)
- NCBI MedGen bibliography: online publication October 29, 2026; PMID 42955519
- Anvisa official oral Wegovy approval announcement, November 4, 2026 (Brazil)
- FDA Drug Safety Communication, November 9, 2026: required NAION safety labeling changes
Historical sources reviewed October 11, 2026. The October 15 Kyinsu opinion and EMA combination-product overview were reviewed October 17. Novo Nordisk’s October 20 sponsor release, the congress poster page and the REDEFINE 1 registry record were reviewed October 22; no peer-reviewed full paper for these particular post hoc analyses was identified. These targeted additions do not imply a fresh review of every earlier trial, a European Commission decision on the proposed Kyinsu change, or approval of CagriSema. October 23: targeted review of the newly linked primary conference abstract(s). Earlier source-review dates and fictional scenes remain unchanged. October 24: targeted review of the October 23 ASN abstracts added below; these are preliminary conference reports, not full-paper reviews. Historical review dates and fictional scenes are unchanged. October 25: reviewed ASN SA-PO0338 and SA-PO0336, scheduled for presentation October 24. These are individual human case-report abstracts, not controlled trials or full-paper reviews; brand and formulation are unspecified. Earlier chapters were not re-reviewed. October 26: targeted review of FDA enforcement event 99867 and the relevant individual product records; dataset dated October 14. Earlier trial sources and fictional scenes were not re-reviewed. October 27: targeted review of Vanda’s Study 3601 sponsor release and ClinicalTrials.gov API record NCT07446439. No full paper or complete numerical safety table reviewed. Historical sources and fictional scenes unchanged. November 2: targeted review of the publisher-hosted FAERS abstract and NCBI bibliographic date. The publisher displays a later issue date. Full-text methods and tables were not accessible; earlier sources and fictional scenes were not re-reviewed. November 5: targeted review of Anvisa’s November 4 oral Wegovy approval notice. The linked official-gazette resolution returned an access error. This addition records the regulator’s announcement, not a new full-label or OASIS 4 review. Historical evidence and fictional scenes were not re-reviewed. November 10: reviewed the November 9 FDA safety communication, including its product table, pooled randomized evidence and comparator-dependent Sentinel findings. This targeted review does not redate earlier sources or confirm implementation in every product label.
Journal update record
2026-10-11 · Published the documented development journey in six chapters, separating fictional scenes from laboratory, animal and human evidence.
2026-10-17 · Added the October 15 CHMP recommendation for Kyinsu, explicitly separating the insulin icodec–semaglutide combination from semaglutide-only products and the recommendation from a final European Commission decision. No fictional scene or historical review date changed.
2026-10-22 · Added the October 20 sponsor-posted REDEFINE 1 women’s analyses, keeping the CagriSema combination, efficacy estimand, post hoc design and absence of a new approval explicit. No fictional scene or historical review date changed.
2026-10-23 · Added the menopause hormone-therapy cohort as preliminary observational evidence, without implying a new indication or causal benefit.
2026-10-24 · Added a preliminary oral-semaglutide kidney study, separating albuminuria from clinical kidney outcomes and noting incomplete methods and safety reporting.
2026-10-25 · Added two October 24 ASN kidney-injury case reports, explicitly reporting dialysis, incomplete recovery where applicable and authors’ limited causality assessments. Preserved the distinction between uncontrolled cases and established trial evidence; no fictional scene changed.
2026-10-26 · Added the FDA-recorded Carolina Infusion compounded-syringe recall, preserving September 10 initiation, October 8 classification and October 14 reporting dates. Distinguished specific formulations and lots from licensed products; patient outcomes are not reported in these records. Historical chapters and fiction are unchanged.
2026-10-27 · Added sponsor-reported tradipitant/semaglutide challenge-study findings, distinguishing the short study from routine treatment and its stale registry status from current recruitment. No new approval or benefit for other medications inferred.
2026-11-02 · Added the previously pending October 29 FAERS paper after verifying its publisher abstract. Preserved the distinction between reporting signals and clinical risk, explicit serious outcomes, publication dates and limited review scope. Fiction and historical review dates are unchanged.
2026-11-05 · Added Anvisa’s November 4 approval announcement for oral Wegovy in eligible adults in Brazil, preserving country, product and population distinctions. Historical chapters, safety findings and fiction are unchanged.
2026-11-10 · Added FDA’s November 9 NAION warning requirement, preserving possible permanent harm, qualified causality and class-level versus product-specific evidence. Fiction and historical chapters are unchanged.
Subject One is fictional. Separate studies, species and populations are not a single patient’s experience. How to read the story